Evidence map›Paper›PMID 22665053›Full record

ReviewOncogene2013

Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects.

M A Pierotti, F Berrino, M Gariboldi, C Melani, A Mogavero, T Negri, P Pasanisi, S Pilotti

Abstract readReview
PubMed Publisher
In one paragraph

Review in Oncogene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Metformin Promotes Anti-tumor Biomarkers in Human Endometrial Cancer Cells.Reproductive sciences (Thousand Oaks, Calif.) · 2020
    Trial
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Review
  14. Metformin: Past, Present, and Future.Current diabetes reports · 2024
    Review
  15. Article
  16. Metformin: A Dual-Role Player in Cancer Treatment and Prevention.International journal of molecular sciences · 2024
    Review
  17. Article
  18. Article
  19. Review
  20. Review

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

M A PierottiScientific Directorate, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy. marco.pierotti@istitutotumori.mi.it
F Berrino
M Gariboldi
C Melani
A Mogavero
T Negri
P Pasanisi
S Pilotti

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding the complexity of cancer and of the underlying regulatory networks provides a new paradigm that tackles cancer development and treatment through a system biology approach, contemporarily acting on various intersecting pathways. Cancer cell metabolism is an old pathogenetic issue that has recently gained new interest as target for therapeutic approaches. More than 70 years ago, Warburg discovered that malignant cells generally have altered metabolism with high rates of glucose uptake and increased glycolysis, even under aerobic condition. Observational studies have provided evidence that impaired metabolism, obesity, hyperglycemia and hyperinsulinemia may have a role in cancer development, progression and prognosis, and actually diabetic and obese patients have increased cancer risk. On the other hand, caloric restriction has been shown to prolong life span and reduce cancer incidence in several animal models, having an impact on different metabolic pathways. Metformin, an antidiabetic drug widely used for over 40 years, mimics caloric restriction acting on cell metabolism at multiple levels, reducing all energy-consuming processes in the cells, including cell proliferation. By overviewing molecular mechanisms of action, epidemiological evidences, experimental data in tumor models and early clinical study results, this review provides information supporting the promising use of metformin in cancer prevention and treatment.

Indexed as

AMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesAnimalsAntineoplastic AgentsAtaxia Telangiectasia Mutated ProteinsCell Cycle ProteinsClinical Trials as TopicDNA-Binding ProteinsHumansMetforminNeoplasmsProtein Serine-Threonine KinasesReceptor, IGF Type 1Transcription FactorsTumor Suppressor Protein p53Tumor Suppressor ProteinsAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesAntineoplastic AgentsAtaxia Telangiectasia Mutated ProteinsATM protein, humanCell Cycle ProteinsDDIT4 protein, humanDNA-Binding ProteinsMetforminProtein Serine-Threonine KinasesReceptor, IGF Type 1STK11 protein, humanTranscription FactorsTumor Suppressor Protein p53Tumor Suppressor Proteins

Identifiers

PMID22665053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.